BPTS   $8.75  -7.89% Market Closed

Biophytis SA
Last Events:

2023-08-06 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-03 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-02 Trend pattern changed from расширяющаяся формация to расходящийся треугольник.

2023-08-02 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-07-30 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-07-30 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.


Current temperature: 2.79
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 1
Target Price Mean 6000.00
Mean unverified/preliminary 6000.00 / 6000.00
Target Price Low / High 6000.00 / 6000.00
Median / STD DEV 6000.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi Sell ActivelyBuy ActivelyBuy
macd None None None
stoch ActivelyBuy None None
ma20 None None None
ma50 ActivelyBuy None None
ma100 ActivelyBuy ActivelyBuy None
Candlestick PatternOct. 31, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US09076G2030
ceo Mr. Stanislas Veillet Ph.D.
Website https://www.biophytis.com
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.